Customized Treatment for the Prevention of Osteoporotic Fracture (골다공증성 골절의 예방을 위한 맞춤치료)

Park Ye-Soo (박예수); Jin-Sung Park (박진성)

Customized Treatment for the Prevention of Osteoporotic Fracture

Journal of Korean Society of Spine Surgery
Abbr : J Kor Spine Sur
2014, 21(4), pp.193-198
Publisher : Korean Society Of Spine Surgery
Research Area : Medicine and Pharmacy > Orthopedic Surgery

Park Ye-Soo ¹, Jin-Sung Park ²

¹한양대학교
²한양대학교 의과대학 구리병원 정형외과학교실

Accredited

ABSTRACT

Study Design: A review of related literature regarding the prevention of osteoporotic fractures. Objective: To discuss the customized treatment and prevention of osteoporotic fractureSummary of Literature Review: Various customized treatments for osteoporosis have been discussed. Materials and Methods: Review of related literatures. Results: It would be best to individualize medications based on each patient’s sex, age, bone density in the spine and hip bones,presence or absence of drug over-use for underlying comorbidities, presence or absence of a gastrointestinal disease, duration ofbisphosphonate usage, and presence or absence of an adverse effect, and drug efficacy according to the analysis of follow-up bonedensity, and compliance. Conclusions: Pharmacotherapy should be combined with various prophylactic therapies to prevent osteoporotic fractures. Variousfactors should be considered as well before selecting an osteoporosis medication. Different types of medications may have differenteffects in their ability to reduce fracture risk in patient with different bone densities and other characteristics.

KEYWORDS

Customized treatment, Prevention, Osteoporotic fracture

Citation status

* References for papers published after 2023 are currently being built.

[journal] Weinstein RS / 1998 / Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone / J Clin Invest 102 : 274~282

[journal] 박예수 / 2012 / Diagnosis and treatment of osteoporosis / 대한의사협회지 / 대한의사협회 55(11) : 1083~1094

[journal] Watts NB / 2010 / American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis / Endocr Pract 16(3Suppl) : 1~37

[journal] Fleisch HA / 1997 / Bisphosphonates : preclinical aspects and use in osteoporosis / Ann Med 29 : 55~62

[journal] 이정환 / 2014 / Analysis of Adherence of Once-yearly Intravenous Zolendronic Acid for Osteoporosis / OSTEOPOROSIS / 대한골다공증학회 12(1) : 22~29

[journal] Bone HG / 2004 / Ten years’ experience with Alendronate for Osteoporosis in Postmenopausal Women / N Engl J Med 350 : 1189~1199

[journal] McClung MR / 2001 / Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group / N Engl J Med 344 : 333~340

[journal] Sørensen HT / 2008 / Use of bisphosphonates among women and risk of atrial fibrillation and flutter : population based case-control study / BMJ 336 : 813~816

[journal] Hong JW / 2010 / Oral bisphosphonaterelated osteonecrosis of the first report in Asia / Osteoporos Int 21 : 847~853

[journal] Khosla S / 2007 / Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research / J Bone Miner Res 22 : 1479~1491

[journal] Lee YK / 2013 / Bisphosphonate use and subsequent hip fracture in South Korea / Osteoporos Int 24 : 2887~2892

[journal] Abrahamsen B / 2009 / Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate : a register-based national cohort study / J Bone Miner Res 24 : 1095~1102

[journal] Das De S / 2010 / A rational approach to management of alendronate-related subtrochanteric frac¬tures / J Bone Joint Surg Br 92 : 679~686

[journal] Shane E / 2014 / Atypical subtrochanteric and diaphyseal femoral fractures : second report of a task force of the american society for bone and mineral research / J Bone Miner Res 29 : 1~23

[journal] McClung MR / 2012 / Efficacy and safety of a novel delayed-release risedronate35 mg once-aweek tablet / Osteoporos Int 23 : 267~276

[journal] Hodges LA / 2012 / Modulation of gastric pH by a buffered soluble effervescent formulation : A possible means of improving gastric tolerability of alendronate / Int J Pharm 432 : 57~62

[journal] Boyd JJ / 2002 / A randomized double-blind trial to compare the efficacy of teriparatide[recombinant human parathyroid hormone I-34)] with alendronate in postmenopausal women with osteoporosis / J Clin Endocrinol Metab 87 : 4528~4535

[journal] Watts NB / 2010 / Long-term use of bisphosphonates in osteoporosis / J Clin Endocrinol Metab 95 : 1555~1565

[journal] McClung M / 2013 / Bisphosphonate Therapy for Osteoporosis : Benefits, Risks, and Drug Holiday / AM J Med 126 : 13~20

KJCKorea
Journal Central

Journal of Korean Society of Spine Surgery 2023 KCI Impact Factor : 0.03